Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $55
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $55
Lake Street Releases a Buy Rating on Harrow Health (HROW)
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $73
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $73
B. Riley Adjusts Price Target on Harrow to $73 From $50, Maintains Buy Rating
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Harrow Is Maintained at Buy by Lake Street
Harrow Analyst Ratings
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $65
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $55
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Gives a Buy Rating to Harrow Health (HROW)
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $50
Harrow Health's Promising Pipeline and Strategic Positioning Spur Buy Rating
Harrow Analyst Ratings
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $45
No Data
No Data